(Q84265156)
Statements
A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors (English)
J R Infante
R Kurzrock
J Spratlin
H A Burris
S G Eckhardt
J Li
K Wu
J M Skolnik
L Hylander-Gans
A Osmukhina
D Huszar